ЛЕЧЕНИЕ ПАЦИЕНТОВ С РЕВМАТОИДНЫМ АРТРИТОМ ПРИ СОЧЕТАННОЙ ПАТОЛОГИИ

D. I. Khusainova, B. A. Bakirov, G. R. Zaripova, L. N. Khusainova, E. M. Aitova, I. L. Bayanova, I. L. Muzaeva, G. A. Khakamova


Аннотация


Сочетанная патология у пациентов с ревматоидным артритом. Выявление взаимосвязи с эффектом от медикаментозной терапии.

 


Ключевые слова


ревматоидный артрит; коморбидная патология; генно-инженерные биологические препараты

Полный текст:

PDF>PDF

Литература


Vertkin A.L., Rumyantsev M.A., Skotnikov A.S. et al. Vestnik semeynoy meditsiny. 2011;(3):40–7.

Gasparyan A.A., Men’shikova I.V., Kanevskaya M.Z. Klinicheskaya meditsina. 2016; 94(10), рр. 745–753.

Gordeev A.V., Galushko E.A., Nasonov E.L. Nauchno-prakticheskaya revmatologiya. 2014;52(4):362–5.

Nasonov E.L., Karateev D.E., Chichasova N.V. Nauchno-prakticheskaya revmatologiya. 2013;51 (6):609–22

Nasonov E.L. Revmatologiya: klinicheskie rekomendatsii [Rheumatology: clinical recommendations]. Moskva: GEOTARMedia; 2010. 752 p.

Nikitina N.M., Afanas’ev I.A., Romanova T.A., Rebrov A.P. Sovremennaya revmatologiya. №1’15. P. 39-43.

Panafidina T.A., Kondrat’eva L.V., Gerasimova E.V. et al. Nauchno-prakticheskaya revmatologiya. 2014;52(3):283–289.

Popkova T.V., Novikova D.S., Nasonov E.L. Consilium medicum. 2008;10(11):128–35.

Starodubtseva I.A., Vasil’eva L.V. Meditsinskiy sovet, №5, 2016. P. 120-123

Boers M, Dijkmans B, Gabriel S, et al. Making an impact on mortality in rheumatoid arthritis. Targeting cardiovascular comorbidity. Arthritis Rheum. 2004;50:1734–9. doi: http://dx.doi.org/10.1002/art.20306

Charlson ME. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–83. doi: 10.1016/0021-9681(87)90171-8

Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66:308–312. doi: 10.1136/ard.2006.057265

Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi 10.1186/ar2669

Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48:54–8. doi: 10.1002/art.10705

Jurgens MS, Jacobs JW, Bijlsma JW. The use of conventional diseasemodifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol. 2011;25(4):523–33. doi:10.1016/j.berh.2011.10.006

Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis. 2004;63:408–10. doi: 10.1136/ard.2003.007526

Kitas GD, Erb N. Tackling ischemic heart disease in rheumatoid arthritis. Rheumatology. 2003;42:607–13. doi: 10.1093/rheumatology/ keg175

Levy L, Fautrel B, Barnetche T, Schaeverbeke T. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Clin Exp Rheumatol. 2008;26:673–9.

Maradit-Kremers H, Nicola PJ, Crowsoon CS, et al. Cardiovascular death in rheumatoid arthritis. Arthritis Rheum. 2005;52:722–32. doi: 10.1002/art.20878

Osiri M, Sattayasomboon Y. Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis. Joint Bone Spine. 2013;80(6):608–12. doi:10.1016/j.jbspin.2013.01.013

Pasceri V, Yeh ETH. A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124–6. doi: 10.1161/01.CIR.100.21.2124

Sattar N, McCrey DW, Capell H, McInnes IB. Explaining how «high-grade» systemic inflammation accelerated vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–63. doi: 10.1161/01.CIR.0000099844.31524.05

Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid.arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7. doi: 10.1136/ard.2009.123919

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recomendattions for the management of rheumatoid arthritis with syntethetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73:492–509. doi: 10.1136/annrheumdis-2013-204573




DOI: https://doi.org/10.12731/2658-6649-2020-12-2-93-105

Ссылки

  • На текущий момент ссылки отсутствуют.


Bookmark and Share


(c) 2020 D. I. Khusainova, B. A. Bakirov, G. R. Zaripova, L. N. Khusainova, E. M. Aitova, I. L. Bayanova, I. L. Muzaeva, G. A. Khakamova

Лицензия Creative Commons
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.

ISSN 2658-6649 (print)

ISSN 2658-6657 (online)

HotLog Яндекс цитирования